Mobilizes national innovation initiative for COVID-19 diagnostics
The National Institutes of Health today announced a replacement initiative aimed toward speeding innovation, this unprecedented global pandemic rapid and widely accessible COVID-19 testing. At an equivalent time, NIH will seek opportunities to maneuver more advanced diagnostic technologies swiftly through the event pipeline toward commercialization and broad availability.
NIH will work closely with the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention and therefore the Biomedical Advanced Research and Development Authority (BARDA) to advance these goals. The stimulus investment supercharges NIH’s strong research efforts already underway focused on prevention and treatment of COVID-19, including the recently announced planned Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership Collins, M.D., Ph.D. “Now is that the time for that unmatched American ingenuity to bring the simplest and most innovative technologies forward to form testing for COVID-19 widely available.”
Up to $500 million over all phases of development. The technologies are going to be put through a highly competitive, rapid three-phase selection process to spot the simplest candidates for at-home or point-of-care tests for COVID-19. Finalists are going to be matched with technical, business and manufacturing experts to extend the chances of success. If certain selected technologies are already relatively far along in development,
They will be placed on a separate track and be immediately advanced to the acceptable step within the commercialization process. The goal is to form many accurate and easy-to-use tests per week available to all or any Americans by the top of summer 2020, and even more in time for the flu season. “Americans are innovators and manufacturers ,” said Bruce J. Tromberg, Ph.D., director of NIH’s National Institute of Biomedical Imaging and Bioengineering (NIBIB).
“We need American tech experts, innovators and entrepreneurs to intensify to at least one of the toughest challenges we’ve faced as a rustic , to assist get us safely back to public spaces.” While diagnostic testing has long been a mainstay of public health, newer technologies offer patient- and user-friendly designs, mobile-device integration, reduced cost and increased accessibility both reception and at the purpose of care. RADx will expand the Point-of-Care Technologies Research Network(link is external) (POCTRN) established several years ago by NIBIB. The network will use a versatile , rapid process to infuse funding and enhance technology designs at key stages of development, expertly from technology innovators, entrepreneurs and business leaders across the country.
POCTRN supports many investigators from multiple universities and businesses through five technology hubs: Emory University/Georgia Institute of Technology, Atlanta Johns Hopkins University, Baltimore Northwestern University, Evanston, Illinois University of Massachusetts school of medicine , Worcester Consortia for Improving Medicine with Innovation & Technology (CIMIT) at Harvard Medical School/Massachusetts General Hospital, Boston so as to roll out new products starting at the top of summer/fall 2020, a rapid, parallel process will allow quick throughput of projects. Projects are going to be assessed at each milestone and must demonstrate significant reach receive continued support. Department of Health and Human Services. For more information about NIH and its programs,
NIH will work closely with the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention and therefore the Biomedical Advanced Research and Development Authority (BARDA) to advance these goals. The stimulus investment supercharges NIH’s strong research efforts already underway focused on prevention and treatment of COVID-19, including the recently announced planned Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership Collins, M.D., Ph.D. “Now is that the time for that unmatched American ingenuity to bring the simplest and most innovative technologies forward to form testing for COVID-19 widely available.”
Up to $500 million over all phases of development. The technologies are going to be put through a highly competitive, rapid three-phase selection process to spot the simplest candidates for at-home or point-of-care tests for COVID-19. Finalists are going to be matched with technical, business and manufacturing experts to extend the chances of success. If certain selected technologies are already relatively far along in development,
They will be placed on a separate track and be immediately advanced to the acceptable step within the commercialization process. The goal is to form many accurate and easy-to-use tests per week available to all or any Americans by the top of summer 2020, and even more in time for the flu season. “Americans are innovators and manufacturers ,” said Bruce J. Tromberg, Ph.D., director of NIH’s National Institute of Biomedical Imaging and Bioengineering (NIBIB).
“We need American tech experts, innovators and entrepreneurs to intensify to at least one of the toughest challenges we’ve faced as a rustic , to assist get us safely back to public spaces.” While diagnostic testing has long been a mainstay of public health, newer technologies offer patient- and user-friendly designs, mobile-device integration, reduced cost and increased accessibility both reception and at the purpose of care. RADx will expand the Point-of-Care Technologies Research Network(link is external) (POCTRN) established several years ago by NIBIB. The network will use a versatile , rapid process to infuse funding and enhance technology designs at key stages of development, expertly from technology innovators, entrepreneurs and business leaders across the country.
POCTRN supports many investigators from multiple universities and businesses through five technology hubs: Emory University/Georgia Institute of Technology, Atlanta Johns Hopkins University, Baltimore Northwestern University, Evanston, Illinois University of Massachusetts school of medicine , Worcester Consortia for Improving Medicine with Innovation & Technology (CIMIT) at Harvard Medical School/Massachusetts General Hospital, Boston so as to roll out new products starting at the top of summer/fall 2020, a rapid, parallel process will allow quick throughput of projects. Projects are going to be assessed at each milestone and must demonstrate significant reach receive continued support. Department of Health and Human Services. For more information about NIH and its programs,
No comments:
Post a Comment